The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...

Pfizer (NYSE:PFE) and other pandemic-era favorites will be back in the investors’ crosshairs following the resignation of Dr.

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

Investing.com -- Shares of vaccine manufacturers Moderna Inc (BMV:MRNA) (NASDAQ:MRNA), Novavax Inc (NASDAQ:NVAX), and Pfizer Inc (NYSE:PFE) fell in today’s trading session, down 5%, 3% ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...

Should you flee the stock market? Not at all. Instead, to protect your portfolio, here are three things every investor should do.

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

Dr. Patrick Soon-Shiong said of rising cancer rates and COVID "it's not a coincidence" regarding both the virus and the shots ...